Pfizer first MNC to get HIV drug patent in India

Global drug major Pfizer's new HIV/AIDS drug Celzentry (generic name: Maraviroc) has become the first known HIV/AIDS treatment drug to get a patent in India, in a significant development against the backdrop of the patent battle between multinational drug companies and patient groups in India.

Maraviroc, the first in a new class of oral HIV medicines developed in the last ten years and expected to become a major blockbuster HIV/AIDS drug globally, was granted a patent in India under the Patent Number 204132, based on the patent application 885/BOM/1999 filed with the Bombay patent office.

Discovered and developed by Pfizer scientists since 1997, Maraviroc, which works by blocking the entry of the virus into human cells, received approval from the US Food and Drug Administration (FDA) only in August 2007, through an accelerated regulatory approval process. One month later, the European Commission gave marketing approval for Maraviroc in Europe. Interestingly, the European Patent Office (EPO) is yet to grant a patent for Maraviroc, citing insufficient data.